We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




AI-Based Staining Technique as Accurate as Traditional Histopathology in Assessing Breast Cancer Biomarker

By LabMedica International staff writers
Posted on 28 Oct 2022
Print article
Image: Virtual HER2 staining of unlabeled breast tissue sections using deep learning (Photo courtesy of UCLA)
Image: Virtual HER2 staining of unlabeled breast tissue sections using deep learning (Photo courtesy of UCLA)

Breast cancer is one the leading causes of cancer death among women globally. Upon breast cancer diagnosis, the testing of HER2 – a protein that promotes cancer cell growth, is routinely carried out to help assess the cancer prognosis and make HER2-directed treatment plans. A standard HER2 test procedure includes taking the breast biopsy, preparing the tissue specimen into thin microscopic slides, staining/dying the slides with specific chemical reagents that highlight the HER2 proteins, and inspecting the stained slides under an optical microscope to provide the pathological report. However, this standard HER2 staining procedure suffers from high costs and long turn-around time as the staining process requires laborious sample treatment steps (typically ~24 hours) performed by experts in a dedicated laboratory facility. Researchers have now developed a computational staining approach powered by deep learning, which performs the HER2 staining without requiring any chemicals.

The research team at UCLA (Los Angeles, CA, USA) captured the autofluorescence information of the unstained breast tissue, which is naturally emitted by biological structures when they absorb light. They further trained a deep neural network that rapidly transforms these stain-free autofluorescence images into virtual histological images, revealing the accurate color and contrast as if the tissue sections were chemically stained for HER2. This computational staining process takes only a few minutes per sample and does not need expensive facilities or toxic chemicals. Using only a computer, the HER2 staining could be accomplished much faster and cost-effectively, accelerating breast cancer assessments and treatment.

Board-certified pathologists blindly validated this AI-based virtual HER2 staining technique in terms of both its diagnostic value and stain quality. The pathologists confirmed that the deep learning-generated images provide the equivalent diagnostic accuracy for HER2 assessment and have a staining quality comparable to the standard images chemically stained in the laboratory. This deep learning-powered virtual HER2 staining approach eliminates the need for costly, laborious, and time-consuming HER2 staining procedures performed by histology experts and could be extended to staining of other cancer-related biomarkers to accelerate the traditional histopathology and diagnostic workflow in clinical settings.

Related Links:
UCLA

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.